文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-PSMA与18F-FDG PET/CT在上皮样血管内皮瘤评估中的比较

68 Ga-PSMA Versus 18 F-FDG PET/CT in the Evaluation of Epithelioid Hemangioendothelioma.
PubMed 文献 · Clin Nucl Med · 2024-06-08

一例32岁男性上皮样血管内皮瘤患者,随访18F-FDG PET/CT发现进展后,行68Ga-PSMA PET/CT评估177Lu-PSMA放射性核素治疗的潜力。肝病灶FDG SUVmax低,病灶-本底比(TBR)为5.1/2.9;68Ga-PSMA PET/CT显示中等PSMA SUVmax,TBR为4.5/1.1。作者认为,本病例中上皮样血管内皮瘤中等TBR的68Ga-PSMA可能对177Lu-PSMA放射性核素治疗有前景。

要点

  • 上皮样血管内皮瘤肝病灶18F-FDG PET/CT显示低FDG SUVmax,TBR为5.1/2.9。
  • 68Ga-PSMA PET/CT显示中等PSMA SUVmax,TBR为4.5/1.1。
  • 作者认为中等TBR的68Ga-PSMA可能对177Lu-PSMA放射性核素治疗有前景。

核心结论

  • 本病例报告表明,上皮样血管内皮瘤中68Ga-PSMA呈中等TBR,可能对177Lu-PSMA放射性核素治疗有前景。

研究设计与样本

  • 本研究报告一例32岁男性上皮样血管内皮瘤患者的病例报告,在随访18F-FDG PET/CT观察到进展表现后行68Ga-PSMA PET/CT评估177Lu-PSMA放射性核素治疗的潜力。

主要发现

  • 肝病灶18F-FDG PET/CT显示低FDG SUVmax,病灶-本底比(TBR)计算为5.1/2.9。
  • 68Ga-PSMA PET/CT显示中等PSMA SUVmax,TBR计算为4.5/1.1。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 32-year-old man with epithelioid hemangioendothelioma was imaged with 68 Ga-PSMA PET/CT to evaluate the potential of 177 Lu-PSMA radionuclide therapy after progression findings were observed on follow-up 18 F-FDG PET/CT imaging. Liver lesions showed low FDG SUV max . The lesion-to-background ratio (TBR) was calculated as 5.1/2.9 on 18 F-FDG PET/CT imaging. However, 68 Ga-PSMA PET/CT showed moderate PSMA SUV max . TBR was calculated as 4.5/1.1. In conclusion, in this case report, we demonstrated that 68 Ga-PSMA with moderate TBR in epithelioid hemangioendothelioma may be promising for 177 Lu-PSMA radionuclide therapy.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Şenses V, Kaplan İ, Kaya F, et al. 68 Ga-PSMA Versus 18 F-FDG PET/CT in the Evaluation of Epithelioid Hemangioendothelioma. Clin Nucl Med. 2024. PMID: 38861414. doi:10.1097/RLU.0000000000005333

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。